ALLIANCES (Lilly) (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Alliances Statement [Line Items]
Net product sales	$ 12,304,000,000	$ 13,654,000,000	$ 17,622,000,000
Cost of products sold - Amortization of intangible assets	858,000,000	607,000,000	353,000,000
Other (income)/expense	205,000,000	(80,000,000)	(334,000,000)
Other intangible assets- Non-refundable upfront, milestone and other licensing payments	2,318,000,000	8,778,000,000
Lilly [Member]
Alliances Statement [Line Items]
Amount of promissory notes assumed in an acquisition that were repaid to Lilly		1,400,000,000
Lilly [Member] | Upfront, milestone and other licensing payments [Member]
Alliances Statement [Line Items]
Other intangible assets- Non-refundable upfront, milestone and other licensing payments	174,000,000	211,000,000
Lilly [Member] | Erbitux [Member]
Alliances Statement [Line Items]
Net product sales	696,000,000	702,000,000	691,000,000
Cost of products sold - Cost of product supply	65,000,000	81,000,000	73,000,000
Cost reimbursements to/(from) alliance partner	(13,000,000)	23,000,000	5,000,000
Lilly [Member] | Erbitux [Member] | Upfront, milestone and other licensing payments [Member]
Alliances Statement [Line Items]
Total upfront, milestone and other licensing payments	500,000,000
Cost of products sold - Amortization of intangible assets	37,000,000	38,000,000	37,000,000
Lilly [Member] | Erbitux [Member] | North America [Member]
Alliances Statement [Line Items]
Distribution fee, percentage of net sales	39.00%
Distribution fees and royalty - Cost of products sold	289,000,000	291,000,000	287,000,000
Lilly and Merck KGaA [Member] | Erbitux [Member] | Japan [Member]
Alliances Statement [Line Items]
Percentage share of pre-tax profit/loss received from the net sales of a collaboration partner to be shared further equally with another collaboration partner.	50.00%
Lilly and Merck KGaA [Member] | Erbitux [Member] | Japan [Member] | Commercialization fee [Member]
Alliances Statement [Line Items]
Other (income)/expense	$ (30,000,000)	$ (37,000,000)	$ (34,000,000)